Bajaj Electricals Update on Chhattisgarh Tax Demand Appeal

Bajaj Electricals Limited has provided an update regarding a tax demand. Following an initial order for FY 2018-19 with a tax demand of ₹1.34 crore, an appellate order dated June 10, 2026, has reduced the demand to ₹92.89 lakh. The company is evaluating further legal options concerning this revised order.

Tax Demand Update from Bajaj Electricals

Bajaj Electricals Limited has issued an update concerning a tax assessment from the Chhattisgarh State Goods and Services Tax Act, 2017. Previously, the Company received an order dated April 25, 2024, detailing an alleged tax demand of ₹1.34 crore for the financial year 2018-19. This initial demand included a general penalty of ₹6.40 lakh, arising from alleged differences in tax payable, input tax credit, B2B tax declared, and credit notes.

Appellate Authority Reduces Demand

In a significant development, Bajaj Electricals has received an appellate order dated June 10, 2026. This order from the Additional Commissioner of State Tax (Appeal), State Tax Chhattisgarh, has partially accepted the Company’s submissions. Consequently, the alleged tax demand has been substantially reduced to ₹92.89 lakh, which includes a revised general penalty of ₹4.28 lakh.

Next Steps and Financial Impact

The management of Bajaj Electricals is currently evaluating appropriate legal remedies. This includes the possibility of filing an appeal before the appropriate appellate tribunal or initiating writ proceedings before the Hon’ble High Court against the recent Appeal Order. The Company has stated that the financial impact of this Appeal Order, should it materialize, would be limited to the extent of the revised demand and penalty. There is no anticipated impact on the operational, financial, or other activities of the Company as a result of this order or assessment.

Source: BSE

Previous Article

Alembic Pharmaceuticals USFDA Grants Tentative Approval for Larotrectinib Capsules

Next Article

Wockhardt Limited Zaynich Secures US FDA Approval, Ushering in New Era of Antibiotic Treatment